Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics

Michiel Kleerebezem*, Sylvie Binda, Peter A. Bron, Gabriele Gross, Colin Hill, Johan E.T. van Hylckama Vlieg, Sarah Lebeer, Reetta Satokari, Arthur C. Ouwehand

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Scopus)

Abstract

The different levels of knowledge described in a translational pipeline (the connection of molecular mechanisms with pre-clinical physiological and human health effects) are not complete for many probiotics. At present, we are not in a position to fully understand the mechanistic basis of many well established probiotic health benefits which, in turn, limits our ability to use mechanisms to predict which probiotics are likely to be effective in any given population. Here we suggest that this concept of a translation pipeline connecting mechanistic insights to probiotic efficacy can support the selection and production of improved probiotic products. Such a conceptual pipeline would also provide a framework for the design of clinical trials to convincingly demonstrate the benefit of probiotics to human health in well-defined subpopulations.

Original languageEnglish
Pages (from-to)55-60
JournalCurrent Opinion in Biotechnology
Volume56
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint Dive into the research topics of 'Understanding mode of action can drive the translational pipeline towards more reliable health benefits for probiotics'. Together they form a unique fingerprint.

Cite this